Targeted Radiotherapy Articles & Analysis: Older
23 news found
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world's leading provider of control systems for the planet's most complex machines, today announced that they have reached their second joint milestone in the clinical commissioning of Neutron ...
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ...
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 ...
BNCT is an emerging, biologically-targeted form of radiotherapy that destroys tumor cells with minimal impact to surrounding healthy cells. ...
BNCT is an emerging, biologically-targeted form of radiotherapy that destroys tumor cells with minimal impact to surrounding healthy cells. ...
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world’s leading provider of control systems for the planet’s most complex machines, today announced that Neutron Therapeutics' nuBeam® BNCT System, using Cosylab's OncologyOne ...
” Proton therapy, a highly advanced form of radiation therapy, targets tumors with greater precision than traditional x-ray-based radiotherapy and can reduce the amount of unnecessary radiation exposure to vulnerable healthy tissue and organs. ...
“We believe that, in sharing our software expertise, we can immensely improve the utility and capability of this novel therapeutic approach.” BNCT targets cancer at the cellular level through selective targeting of tumor cells with a boron containing drug, followed by activation of the drug by a neutron beam. ...
GT Medical Technologies, Inc. today announced it was named a winner of the Innovator of the Year in the small company category at the 2021 Governor's Celebration of Innovation, presented live on stage by the Arizona Technology Council and the Arizona Commerce Authority on October 13. GT Medical Technologies received this accolade in recognition of GammaTile® Therapy, its Surgically Targeted ...
TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry-Expert Theater session focused on advancements in BNCT at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 24-27, 2021. The session, “New Era in Biologically-Targeted ...
“TAE Life Sciences is also developing comprehensive boron target drugs and a neutron technology product portfolio to enable BNCT as a new cancer treatment modality for patients globally. ...
The requirements for medical devices that are used for BNCT treatment differ substantially from the requirements for systems used in conventional radiotherapy, as material properties become degraded by neutron irradiation. ...
It's the first device of its kind, and its ability to deliver safe and effective Surgically Targeted Radiation Therapy (STaRT) for patients is groundbreaking in the neuro-oncology community." ...
Drugs being developed to expand indications for treatment and improve efficacy of BNCT for cancer treatment Only company developing comprehensive new target drug portfolio and accelerator-based neutron system TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today ...
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical Technologies’ GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent glioblastoma (GBM). Novocure’s TTFields are electric fields that disrupt cancer cell ...
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman ...
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman ...
GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumors. The study will evaluate the safety and effectiveness of GammaTile Therapy in a ...
TAE Life Sciences (TLS), a biologically-targeted radiation therapy company developing a breakthrough, accelerator-based boron neutron capture therapy (BNCT) system, today announced that it has entered into an agreement with National Center of Oncological Hadrontherapy (CNAO) to provide its Alphabeam™ Neutron System for the treatment of invasive, recurrent and difficult to treat cancers. ...
Currently in Lead Optimization stage, the Debio 0228 program is set to identify a Development Candidate with best-in-class potential, designed to selectively destroy tumor cells that express the CAIX target. The selected compound will be developed using a theranostic approach, a combination of diagnostic and therapeutic features with the same compound, allowing the ...